| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Tango Therapeutics, Inc. | General Counsel | Common Stock | 66,014 | $208,697 | $3.16 | 05 Feb 2025 | Direct |
| Tango Therapeutics, Inc. | General Counsel | Stock Option (Right to Buy) | 164,175 | 03 Feb 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | 04 Feb 2025 | 2 | -$16,369 | 4 | General Counsel | 06 Feb 2025, 20:21 |
| TNGX | Tango Therapeutics, Inc. | 03 Feb 2025 | 2 | $0 | 4 | General Counsel | 05 Feb 2025, 19:30 |
| TNGX | Tango Therapeutics, Inc. | 06 Feb 2024 | 2 | -$34,951 | 4 | General Counsel | 08 Feb 2024, 21:09 |
| TNGX | Tango Therapeutics, Inc. | 01 Feb 2024 | 2 | $0 | 4 | General Counsel | 05 Feb 2024, 16:19 |
| TNGX | Tango Therapeutics, Inc. | 01 Mar 2023 | 2 | $0 | 4 | General Counsel | 02 Mar 2023, 15:06 |
| TNGX | Tango Therapeutics, Inc. | 01 Feb 2022 | 1 | $0 | 4 | General Counsel | 03 Feb 2022, 15:30 |
| TNGX | Tango Therapeutics, Inc. | 14 Oct 2021 | 0 | $0 | 3 | General Counsel, Corporate Secretary | 01 Nov 2021, 16:15 |